{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cany J"],"funding":["ZonMw"],"pagination":["e1017701"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4485802"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(7)"],"pubmed_abstract":["Adoptive transfer of allogeneic natural killer (NK) cells represents a promising treatment approach against cancer, including acute myeloid leukemia (AML). Previously, we reported a cytokine-based culture method for the generation of NK cell products with high cell number and purity. In this system, CD34<sup>+</sup> hematopoietic progenitor cells (HPC) were expanded and differentiated into NK cells under stroma-free conditions in the presence of IL-15 and IL-2. We show that combining IL-15 with IL-12 drives the generation of more mature and highly functional NK cells. In particular, replacement of IL-2 by IL-12 enhanced the cytolytic activity and IFNγ production of HPC-NK cells toward cultured and primary AML cells <i>in vitro</i>, and improved antileukemic responses in NOD/SCID-IL2Rγnull (NSG) mice bearing human AML cells. Phenotypically, IL-12 increased the frequency of HPC-NK cells expressing NKG2A and killer immunoglobulin-like receptor (KIR), which were more responsive to target cell stimulation. In addition, NK15/12 cell products demonstrated superior maturation potential, resulting in >70% positivity for CD16 and/or KIR within 2 weeks after infusion into NSG mice. We predict that higher functionality and faster <i>in vivo</i> maturation will favor HPC-NK cell alloreactivity toward malignant cells in patients, making this cytokine combination an attractive strategy to generate clinical HPC-NK cell products for cancer adoptive immunotherapy."],"journal":["Oncoimmunology"],"pubmed_title":["Combined IL-15 and IL-12 drives the generation of CD34<sup>+</sup>-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer."],"pmcid":["PMC4485802"],"funding_grant_id":["11600101"],"pubmed_authors":["van der Voort R","van der Waart AB","Tordoir M","Spanholtz J","Schaap NM","Cany J","Jansen JH","Dolstra H"],"additional_accession":[]},"is_claimable":false,"name":"Combined IL-15 and IL-12 drives the generation of CD34<sup>+</sup>-derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer.","description":"Adoptive transfer of allogeneic natural killer (NK) cells represents a promising treatment approach against cancer, including acute myeloid leukemia (AML). Previously, we reported a cytokine-based culture method for the generation of NK cell products with high cell number and purity. In this system, CD34<sup>+</sup> hematopoietic progenitor cells (HPC) were expanded and differentiated into NK cells under stroma-free conditions in the presence of IL-15 and IL-2. We show that combining IL-15 with IL-12 drives the generation of more mature and highly functional NK cells. In particular, replacement of IL-2 by IL-12 enhanced the cytolytic activity and IFNγ production of HPC-NK cells toward cultured and primary AML cells <i>in vitro</i>, and improved antileukemic responses in NOD/SCID-IL2Rγnull (NSG) mice bearing human AML cells. Phenotypically, IL-12 increased the frequency of HPC-NK cells expressing NKG2A and killer immunoglobulin-like receptor (KIR), which were more responsive to target cell stimulation. In addition, NK15/12 cell products demonstrated superior maturation potential, resulting in >70% positivity for CD16 and/or KIR within 2 weeks after infusion into NSG mice. We predict that higher functionality and faster <i>in vivo</i> maturation will favor HPC-NK cell alloreactivity toward malignant cells in patients, making this cytokine combination an attractive strategy to generate clinical HPC-NK cell products for cancer adoptive immunotherapy.","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Jul","modification":"2025-04-04T12:51:40.457Z","creation":"2019-03-27T01:54:15Z"},"accession":"S-EPMC4485802","cross_references":{"pubmed":["26140247"],"doi":["10.1080/2162402x.2015.1017701","10.1080/2162402X.2015.1017701"]}}